Search

Your search keyword '"Hassel, Jessica C"' showing total 991 results
Start Over Author "Hassel, Jessica C"
991 results on '"Hassel, Jessica C"'

101. Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Author

Van Allen, Eliezer M., primary, Wagle, Nikhil, primary, Sucker, Antje, primary, Treacy, Daniel J., primary, Johannessen, Cory M., primary, Goetz, Eva M., primary, Place, Chelsea S., primary, Taylor-Weiner, Amaro, primary, Whittaker, Steven, primary, Kryukov, Gregory V., primary, Hodis, Eran, primary, Rosenberg, Mara, primary, McKenna, Aaron, primary, Cibulskis, Kristian, primary, Farlow, Deborah, primary, Zimmer, Lisa, primary, Hillen, Uwe, primary, Gutzmer, Ralf, primary, Goldinger, Simone M., primary, Ugurel, Selma, primary, Gogas, Helen J., primary, Egberts, Friederike, primary, Berking, Carola, primary, Trefzer, Uwe, primary, Loquai, Carmen, primary, Weide, Benjamin, primary, Hassel, Jessica C., primary, Gabriel, Stacey B., primary, Carter, Scott L., primary, Getz, Gad, primary, Garraway, Levi A., primary, and Schadendorf, Dirk, primary

Published
2023
Full Text
View/download PDF

102. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Author

Franklin, Cindy, primary, Mohr, Peter, additional, Bluhm, Leonie, additional, Meier, Friedegund, additional, Garzarolli, Marlene, additional, Weichenthal, Michael, additional, Kähler, Katharina, additional, Grimmelmann, Imke, additional, Gutzmer, Ralf, additional, Utikal, Jochen, additional, Terheyden, Patrick, additional, Herbst, Rudolf, additional, Haferkamp, Sebastian, additional, Pfoehler, Claudia, additional, Forschner, Andrea, additional, Leiter, Ulrike, additional, Ziller, Fabian, additional, Meiss, Frank, additional, Ulrich, Jens, additional, Kreuter, Alexander, additional, Gebhardt, Christoffer, additional, Welzel, Julia, additional, Schilling, Bastian, additional, Kaatz, Martin, additional, Scharfetter-Kochanek, Karin, additional, Dippel, Edgar, additional, Nashan, Dorothee, additional, Sachse, Michael, additional, Weishaupt, Carsten, additional, Löffler, Harald, additional, Gambichler, Thilo, additional, Loquai, Carmen, additional, Heinzerling, Lucie, additional, Grabbe, Stephan, additional, Debus, Dirk, additional, Schley, Gaston, additional, Hassel, Jessica C, additional, Weyandt, Gerhard, additional, Trommer, Maike, additional, Lodde, Georg, additional, Placke, Jan-Malte, additional, Zimmer, Lisa, additional, Livingstone, Elisabeth, additional, Becker, Jürgen Christian, additional, Horn, Susanne, additional, Schadendorf, Dirk, additional, and Ugurel, Selma, additional

Published
2023
Full Text
View/download PDF

103. Supplementary Table 1 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

104. Supplementary Figure 1 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

105. Supplementary Figure 2 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

106. Supplementary Table 3 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

107. Supplementary Table 1 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Foppen, Marnix Geukes, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Romano, Emanuela, primary, Khammari, Amir, primary, Dreno, Brigitte, primary, Capone, Mariaelena, primary, Ascierto, Paolo A., primary, Di Giacomo, Anna Maria, primary, Maio, Michele, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Hassel, Jessica C., primary, Eigentler, Thomas K., primary, Martus, Peter, primary, Wolchok, Jedd D., primary, Blank, Christian, primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

108. Supplementary Figure 1 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

109. Supplementary Methods from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

110. Table S1 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

Author

Spassova, Ivelina, primary, Ugurel, Selma, primary, Terheyden, Patrick, primary, Sucker, Antje, primary, Hassel, Jessica C., primary, Ritter, Cathrin, primary, Kubat, Linda, primary, Habermann, Daniel, primary, Farahpour, Farnoush, primary, Saeedghalati, Mohammadkarim, primary, Peiffer, Lukas, primary, Kumar, Rajiv, primary, Schrama, David, primary, Hoffmann, Daniel, primary, Schadendorf, Dirk, primary, and Becker, Jürgen C., primary

Published
2023
Full Text
View/download PDF

111. Supplementary Figure 4 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

112. Supplementary Methods from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

113. Figure S2 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

Author

Spassova, Ivelina, primary, Ugurel, Selma, primary, Terheyden, Patrick, primary, Sucker, Antje, primary, Hassel, Jessica C., primary, Ritter, Cathrin, primary, Kubat, Linda, primary, Habermann, Daniel, primary, Farahpour, Farnoush, primary, Saeedghalati, Mohammadkarim, primary, Peiffer, Lukas, primary, Kumar, Rajiv, primary, Schrama, David, primary, Hoffmann, Daniel, primary, Schadendorf, Dirk, primary, and Becker, Jürgen C., primary

Published
2023
Full Text
View/download PDF

114. Supplementary Figure 6 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

115. Supplementary Figure 3 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

116. Supplementary Table 2 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

117. Supplementary Figure 7 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

118. Supplementary Table 2 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Foppen, Marnix Geukes, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Romano, Emanuela, primary, Khammari, Amir, primary, Dreno, Brigitte, primary, Capone, Mariaelena, primary, Ascierto, Paolo A., primary, Di Giacomo, Anna Maria, primary, Maio, Michele, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Hassel, Jessica C., primary, Eigentler, Thomas K., primary, Martus, Peter, primary, Wolchok, Jedd D., primary, Blank, Christian, primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

119. Supplementary Figure 4 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

120. Supplementary Figure 5 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Author

Poschke, Isabel C., primary, Hassel, Jessica C., primary, Rodriguez-Ehrenfried, Aaron, primary, Lindner, Katharina A.M., primary, Heras-Murillo, Ignacio, primary, Appel, Lena M., primary, Lehmann, Johanna, primary, Lövgren, Tanja, primary, Wickström, Stina L., primary, Lauenstein, Claudia, primary, Roth, Jasmin, primary, König, Anna-Katharina, primary, Haanen, John B.A.G., primary, van den Berg, Joost, primary, Kiessling, Rolf, primary, Bergmann, Frank, primary, Flossdorf, Michael, primary, Strobel, Oliver, primary, and Offringa, Rienk, primary

Published
2023
Full Text
View/download PDF

121. Supplementary Table 3 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Foppen, Marnix Geukes, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Romano, Emanuela, primary, Khammari, Amir, primary, Dreno, Brigitte, primary, Capone, Mariaelena, primary, Ascierto, Paolo A., primary, Di Giacomo, Anna Maria, primary, Maio, Michele, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Hassel, Jessica C., primary, Eigentler, Thomas K., primary, Martus, Peter, primary, Wolchok, Jedd D., primary, Blank, Christian, primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

122. Supplementary Table 2 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

123. Supplementary Figure 3 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Author

Martens, Alexander, primary, Wistuba-Hamprecht, Kilian, primary, Foppen, Marnix Geukes, primary, Yuan, Jianda, primary, Postow, Michael A., primary, Wong, Phillip, primary, Romano, Emanuela, primary, Khammari, Amir, primary, Dreno, Brigitte, primary, Capone, Mariaelena, primary, Ascierto, Paolo A., primary, Di Giacomo, Anna Maria, primary, Maio, Michele, primary, Schilling, Bastian, primary, Sucker, Antje, primary, Schadendorf, Dirk, primary, Hassel, Jessica C., primary, Eigentler, Thomas K., primary, Martus, Peter, primary, Wolchok, Jedd D., primary, Blank, Christian, primary, Pawelec, Graham, primary, Garbe, Claus, primary, and Weide, Benjamin, primary

Published
2023
Full Text
View/download PDF

126. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Author

Weber, Jeffrey S, D'Angelo, Sandra P, Minor, David, Hodi, F Stephen, Gutzmer, Ralf, Neyns, Bart, Hoeller, Christoph, Khushalani, Nikhil I, Miller, Wilson H, Jr, Lao, Christopher D, Linette, Gerald P, Thomas, Luc, Lorigan, Paul, Grossmann, Kenneth F, Hassel, Jessica C, Maio, Michele, Sznol, Mario, Ascierto, Paolo A, Mohr, Peter, Chmielowski, Bartosz, Bryce, Alan, Svane, Inge M, Grob, Jean-Jacques, Krackhardt, Angela M, Horak, Christine, Lambert, Alexandre, Yang, Arvin S, and Larkin, James

Published
2015
Full Text
View/download PDF

129. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Author

Van Allen, Eliezer M., Miao, Diana, Schilling, Bastian, Shukla, Sachet A., Blank, Christian, Zimmer, Lisa, Sucker, Antje, Hillen, Uwe, Foppen, Marnix H. Geukes, Goldinger, Simone M., Utikal, Jochen, Hassel, Jessica C., Weide, Benjamin, Kaehler, Katharina C., Loquai, Carmen, Mohr, Peter, Gutzmer, Ralf, Dummer, Reinhard, Gabriel, Stacey, Wu, Catherine J., Schadendorf, Dirk, and Garraway, Levi A.

Published
2015

131. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment

Author

Strobel, Sophia B., Machiraju, Devayani, Kälber, Katharina A., and Hassel, Jessica C.

Subjects
Research Report, Male, Cancer Research, COVID-19 Vaccines, Skin Neoplasms, COVID-19 vaccination, Vaccination, Immunology, Immune-checkpoint inhibitors, COVID-19, Cancer patients, Middle Aged, Oncology, Adverse events, Humans, Immunology and Allergy, Female, Immune Checkpoint Inhibitors, Retrospective Studies
Abstract

To date, few data are available regarding Adverse events (AEs) in cancer patients who are vaccinated for coronavirus disease 2019 (COVID-19) while being actively treated with Immune-checkpoint inhibitors (ICIs). We aimed to assess the safety of COVID-19 vaccines approved in Germany. Specifically, we investigated the frequency of general side effects and immune-related AEs of COVID-19 vaccination. A triage survey was used to collect the following information for patients with metastatic skin cancer: vaccine type, date of receipt of each dose of vaccine, and self-reported side effects. Clinical data were retrieved from the patients’ medical records. Of 130 patients with metastatic skin cancer, 89 patients were on immunotherapy and received COVID-19 vaccination. Of these 89 patients (median age: 64 years; 57 [64%] men), 89% had melanoma, and 71% received ICI therapy with a PD-1 antibody. Eighty-eight percent received an mRNA-based COVID-19 vaccination. The median follow-up time was 125 days after the first vaccination, and 84 days after the second. The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%). Grade 3 irAEs were reported in eight patients, seven of whom were on nivolumab plus ipilimumab combination treatment. Of the 19 patients vaccinated within 72 h before/after ICI, five developed irAEs within 17 days (1–17 days). This small cohort study suggests that approved COVID-19 vaccinations are safe for use in cancer patients receiving ICIs. However, some precautions should be taken, especially regarding the timing of vaccination and ICI treatment. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-021-03133-w.

Published
2021
Full Text
View/download PDF

134. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Author

Weber, Jeffrey S., primary, Schadendorf, Dirk, additional, Del Vecchio, Michele, additional, Larkin, James, additional, Atkinson, Victoria, additional, Schenker, Michael, additional, Pigozzo, Jacopo, additional, Gogas, Helen, additional, Dalle, Stéphane, additional, Meyer, Nicolas, additional, Ascierto, Paolo A., additional, Sandhu, Shahneen, additional, Eigentler, Thomas, additional, Gutzmer, Ralf, additional, Hassel, Jessica C., additional, Robert, Caroline, additional, Carlino, Matteo S., additional, Di Giacomo, Anna Maria, additional, Butler, Marcus O., additional, Muñoz-Couselo, Eva, additional, Brown, Michael P., additional, Rutkowski, Piotr, additional, Haydon, Andrew, additional, Grob, Jean-Jacques, additional, Schachter, Jacob, additional, Queirolo, Paola, additional, de la Cruz-Merino, Luis, additional, van der Westhuizen, Andre, additional, Menzies, Alexander M., additional, Re, Sandra, additional, Bas, Tuba, additional, de Pril, Veerle, additional, Braverman, Julia, additional, Tenney, Daniel J., additional, Tang, Hao, additional, and Long, Georgina V., additional

Published
2023
Full Text
View/download PDF

136. Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study

Author

Thiem, Alexander, primary, Mashhadiakbar, Pegah, additional, Cussigh, Christiane, additional, Hassel, Jessica C., additional, Grimmelmann, Imke, additional, Gutzmer, Ralf, additional, Schlaak, Max, additional, Heppt, Markus V., additional, Dücker, Pia, additional, Hüning, Svea, additional, Schulmeyer, Lena, additional, Schilling, Bastian, additional, Haferkamp, Sebastian, additional, Ziemer, Mirjana, additional, Moritz, Rose K. C., additional, Hagelstein, Victoria, additional, Terheyden, Patrick, additional, Posch, Christian, additional, Gaiser, Maria R., additional, Kropp, Peter, additional, Emmert, Steffen, additional, Müller, Britta, additional, and Tietze, Julia K., additional

Published
2022
Full Text
View/download PDF

138. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Author

Chesney, Jason, primary, Lewis, Karl D, additional, Kluger, Harriet, additional, Hamid, Omid, additional, Whitman, Eric, additional, Thomas, Sajeve, additional, Wermke, Martin, additional, Cusnir, Mike, additional, Domingo-Musibay, Evidio, additional, Phan, Giao Q, additional, Kirkwood, John M, additional, Hassel, Jessica C, additional, Orloff, Marlana, additional, Larkin, James, additional, Weber, Jeffrey, additional, Furness, Andrew J S, additional, Khushalani, Nikhil I, additional, Medina, Theresa, additional, Egger, Michael E, additional, Graf Finckenstein, Friedrich, additional, Jagasia, Madan, additional, Hari, Parameswaran, additional, Sulur, Giri, additional, Shi, Wen, additional, Wu, Xiao, additional, and Sarnaik, Amod, additional

Published
2022
Full Text
View/download PDF

139. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis

Author

Müller-Jensen, Leonie, primary, Zierold, Sarah, additional, Versluis, Judith M, additional, Boehmerle, Wolfgang, additional, Huehnchen, Petra, additional, Endres, Matthias, additional, Mohr, Raphael, additional, Compter, Annette, additional, Blank, Christian U, additional, Hagenacker, Tim, additional, Meier, Friedegund, additional, Reinhardt, Lydia, additional, Gesierich, Anja, additional, Salzmann, Martin, additional, Hassel, Jessica C, additional, Ugurel, Selma, additional, Zimmer, Lisa, additional, Banks, Patricia, additional, Spain, Lavinia, additional, Soon, Jennifer A, additional, Enokida, Tomohiro, additional, Tahara, Makoto, additional, Kähler, Katharina C, additional, Seggewiss-Bernhardt, Ruth, additional, Harvey, Catriona, additional, Long, Georgina V, additional, Schöberl, Florian, additional, von Baumgarten, Louisa, additional, Hundsberger, Thomas, additional, Schlaak, Max, additional, French, Lars E, additional, Knauss, Samuel, additional, and Heinzerling, Lucie M, additional

Published
2022
Full Text
View/download PDF

141. Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

Author

DeTemple, Viola K., primary, Hassel, Jessica C., additional, Sachse, Michael M., additional, Grimmelmann, Imke, additional, Leiter, Ulrike, additional, Gebhardt, Christoffer, additional, Eckardt, Julia, additional, Pföhler, Claudia, additional, Angela, Yenny, additional, Hübbe, Hanna, additional, and Gutzmer, Ralf, additional

Published
2022
Full Text
View/download PDF

145. Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?

Author

Sachpekidis, Christos, Stein-Thoeringer, Christoph K., Kopp-Schneider, Annette, Weru, Vivienn, Dimitrakopoulou-Strauss, Antonia, and Hassel, Jessica C.

Subjects
COMPUTED tomography, IMMUNE checkpoint inhibitors, CANCER patients, IMMUNOTHERAPY, MELANOMA, GUT microbiome
Abstract

Aim: The development of biomarkers that can reliably and early predict response to immune checkpoint inhibitors (ICIs) is crucial in melanoma. In recent years, the gut microbiome has emerged as an important regulator of immunotherapy response, which may, moreover, serve as a surrogate marker and prognosticator in oncological patients under immunotherapy. Aim of the present study is to investigate if physiologic colonic [18F]FDG uptake in PET/CT before start of ICIs correlates with clinical outcome of metastatic melanoma patients. The relation between [18F]FDG uptake in lymphoid cell-rich organs and long-term patient outcome is also assessed. Methodology: One hundred nineteen stage IV melanoma patients scheduled for immunotherapy with ipilimumab, applied either as monotherapy or in combination with nivolumab, underwent baseline [18F]FDG PET/CT. PET/CT data analysis consisted of standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) calculations in the colon as well as measurements of the colon-to-liver SUV ratios (CLRmean, CLRmax). Visual grading of colon uptake based on a four-point scale was also performed. Moreover, the spleen-to-liver SUV ratios (SLRmean, SLRmax) and the bone marrow-to-liver SUV ratios (BLRmean, BLRmax) were calculated. We also measured serum lipopolysaccharide (LPS) levels as a marker for bacterial translocation and surrogate for mucosal defense homeostasis. The results were correlated with patients' best clinical response, progression-free survival (PFS), and overall survival (OS) as well as clinical signs of colitis. Results: Median follow-up [95%CI] from the beginning of immunotherapy was 64.6 months [61.0–68.6 months]. Best response to treatment was progressive disease (PD) for 60 patients, stable disease (SD) for 37 patients, partial response (PR) for 18 patients, and complete response (CR) for 4 patients. Kaplan–Meier curves demonstrated a trend for longer PFS and OS in patients with lower colonic SUV and CLR values; however, no statistical significance for these parameters as prognostic factors was demonstrated. On the other hand, patients showing disease control as best response to treatment (SD, PR, CR) had significantly lower colonic MTV and TLG than those showing PD. With regard to lymphoid cell-rich organs, significantly lower baseline SLRmax and BLRmax were observed in patients responding with disease control than progression to treatment. Furthermore, patients with lower SLRmax and BLRmax values had a significantly longer OS when dichotomized at their median. In multivariate analysis, PET parameters that were found to significantly adversely correlate with patient survival were colonic MTV for PFS, colonic TLG for PFS, and BLRmax for PFS and OS. Conclusions: Physiologic colonic [18F]FDG uptake in PET/CT, as assessed by means of SUV, before start of ipilimumab-based treatment does not seem to independently predict patient survival of metastatic melanoma. On the other hand, volumetric PET parameters, such as MTV and TLG, derived from the normal gut may identify patients showing disease control to immunotherapy and significantly correlate with PFS. Moreover, the investigation of glucose metabolism in the spleen and the bone marrow may offer prognostic information. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results